

Freedom of Information Request	FOI 23-232	31 st May 2023
--------------------------------	------------	---------------------------

Question 1

How many patients has your Organisations treated in the past 3 months for Chronic Lymphocytic Leukaemia (CLL)? In case you do not treat CLL, which other Organisation do you refer patients needing treatment to?

For the period January to March 2023, 12 patients were recorded with a primary diagnosis of chronic lymphocytic leukaemia (CLL) with an inpatient or daycase stay.

Question 2

How many Chronic Lymphocytic Leukaemia (CLL) patients have been treated in the past 3 months with the following:

The Health Board is unable to provide information on the number of patients treated, however, please find below the quantities dispensed, across Health Board pharmacies for 'haematology only' for the period February 2023 to April 2023.

BR (bendamustine + rituximab)

Calquence (acalabrutinib)

FCR (fludarabine + cyclophosphamide + rituximab)

Gazyva (obinutuzumab) + chlorambucil

Imbruvica (ibrutinib)

Venclexta (venetoclax)

Venclexta (venetoclax) + Gazyva (obinutuzumab)

Venclexta (venetoclax) + rituximab

Zydelig (idelalisib) + rituximab

Any other systemic anti-cancer therapy

Wait and watch (monitoring only, no active treatment)

Drug	Quantity
ACALABRUTINIB 100 mg Capsules 60 Capsule Pack	90
BENDAMUSTINE HYDROCHLORIDE 100 mg Intravenous Infusion 5 Vial Pack	2
BENDAMUSTINE HYDROCHLORIDE 25 mg Intravenous Infusion 5 Vial Pack	8
CHLORAMBUCIL 2 mg Tablets 25 Tablet Pack	4
CYCLOPHOSPHAMIDE (1251mg-1500mg) in SODIUM CHLOR 0.9%(500mL) Intravenous Infusion 1 Bag Pack	1
CYCLOPHOSPHAMIDE (2501mg - 2750mg) IN MULTILAYER PN BAG Intravenous Infusion 1 Bag Pack	4
CYCLOPHOSPHAMIDE (2751mg - 3000mg) IN MULTILAYER PN BAG Intravenous Infusion 1 Bag Pack	2
CYCLOPHOSPHAMIDE (3001mg - 3250mg) IN MULTILAYER PN BAG Intravenous Infusion 1 Bag Pack	1
CYCLOPHOSPHAMIDE 150 mg in 7.5mL Intravenous	12

Drug	Quantity
Injection 1 Syringe Pack	
CYCLOPHOSPHAMIDE 400 mg in 20mL Intravenous Injection 1 Syringe Pack	39
CYCLOPHOSPHAMIDE 50 mg Tablets 100 Tablet Pack	9
CYCLOPHOSPHAMIDE 500 mg in 25mL Intravenous Injection 1 Syringe Pack	57
CYCLOPHOSPHAMIDE 700 mg in 35mL Intravenous Injection 1 Syringe Pack	85
CYCLOPHOSPHAMIDE 800 mg in 40mL Intravenous Injection 1 Pre-Filled Syringe Pack	94
IBRUTINIB 140 mg Tablets 28 Tablet Pack	12
IBRUTINIB 280 mg Tablets 28 Tablet Pack	12
IBRUTINIB 420 mg Tablets 28 Tablet Pack	58
IBRUTINIB 560 mg Tablets 28 Tablet Pack	6
OBINUTUZUMAB 1000 mg in 40mL Intravenous Infusion 1 Vial Pack	2
RITUXIMAB (MABTHERA) 1400 mg in 11.7mL Subcutaneous Injection 1 Vial Pack	52
RITUXIMAB (MABTHERA) 500 mg in 50mL Intravenous Infusion 1 Vial Pack	1
RITUXIMAB (RIXATHON) 100 mg in 10mL Intravenous Infusion 2 Vial Pack	61
RITUXIMAB (RIXATHON) 500 mg in 50mL Intravenous Infusion 1 Vial Pack	61
VENETOCLAX 100 mg Tablets 112 Tablet Pack	4
VENETOCLAX 100 mg Tablets 14 Tablet Pack	6

Question 3

If your Organisation does treat Chronic Lymphocytic Leukaemia patients, do you currently participate in any ongoing clinical trials for the treatment of CLL? If so, can you please provide the name of each trial along with the number of patients taking part?

The Health Board currently have two studies for CLL:

Flair:- Front Line Therapy in CLL: Assessment of Ibrutinib-containing regimes
Currently 4 patients in follow-up

Improve:- A multi-centre randomised controlled trial examining the effects of temporarily pausing Bruton Tyrosine Kinase inhibitor therapy to coincide with SARSCoV-2 vaccination and its impact on immune responses in patients with Chronic Lymphocytic Leukaemia

Currently 3 patients consented but 1 classed as recruited as the other 2 are awaiting vaccine dates to be randomised. Recruitment is ongoing.